Merus Labs Appoints Geoff Morrow as Vice President, Business Development

TORONTO, ONTARIO--(Marketwired - Feb. 4, 2015) - Merus Labs International Inc. MSLMSLI ("Merus" or "the Company") today announced the appointment of Geoff Morrow as Vice President, Business Development.

Mr. Morrow has over 15 years' experience in the pharmaceutical industry. Most recently, he held the position of Commercial Lead, Urology at Allergan Canada. Previously, Mr. Morrow was Director, Business Development and Corporate Planning at Astellas Pharma Canada. In addition, Geoff held US-based management roles at InVentiv Health and Eli Lilly and Canadian-based roles at AstraZeneca.

"We are pleased to welcome Geoff to Merus' executive team," said Barry Fishman, Chief Executive Officer of Merus. "His deep experience and strong global pharmaceutical network will be valuable assets as we execute our ambitious growth strategy."

The Company plans to release its first quarter 2015 earnings after market close on Wednesday, February 11, 2015. Merus will hold a conference call at 8:30am EST on Thursday, February 12, 2015 to discuss the results. Dial-in information for the conference call will be provided in the earnings release.

About Merus Labs International Inc.

Merus Labs is a specialty pharmaceutical company focused on acquiring established products. The Company leverages its expertise in European and North American markets to optimize the value of underdeveloped pharmaceutical assets.

Cautionary Statement

Certain statements contained in this press release may constitute "forward-looking statements" within the meaning of Section 21E (i) (1) of the United States Securities Exchange Act of 1934. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Merus' actual results to be materially different from any future results expressed or implied by these statements. Such factors include the following: general economic and business conditions, changes in demand for Merus' products, changes in competition, the ability of Merus to complete future acquisitions and to integrate these acquisitions into its business, Merus' ability to complete future debt and/or equity financings required to complete future acquisitions, interest rate fluctuations, currency exchange rate fluctuations, dependence upon and availability of qualified personnel and changes in government regulation. In light of these and other uncertainties, the forward-looking statements included in this press release should not be regarded as a representation by Merus that Merus' plans and objectives will be achieved. These forward-looking statements speak only as of the date of this press release, and we undertake no obligation to update or revise the statements.

FOR FURTHER INFORMATION PLEASE CONTACT:
Merus Labs International Inc.
(416) 593-3725


Or contact our investor relations department at:
info@meruslabs.com